BioLineRx reports Q1 EPS 0c vs. 0c last year

Reports Q1 revenue $300,000 vs. $6.90M last year. “Following our announcement last November that we out-licensed APHEXDA(R), our FDA-approved stem cell mobilization agent, to Ayrmid Ltd., we have been actively evaluating new assets in the areas of oncology and rare disease where we can leverage our drug development and regulatory expertise to bring new medicines to market,” said Philip Serlin, CEO of BioLineRx (BLRX). “I remain optimistic that we will announce a meaningful transaction this year.” “At the same time, APHEXDA is performing well under the stewardship of Ayrmid, and I believe this license agreement will contribute significant long-term value to our company,” Serlin concluded.